ReneuBio is a Stanford spinout developing AI-enabled small-molecule therapeutics for the aging brain.

We combine deep expertise in aging biology with an agentic AI drug design platform that integrates medicinal chemistry, biology, pharmacology, and toxicology to design development-ready compounds with a higher probability of clinical success.

Our platform identifies molecular signals associated with clinical failure and uses these insights to guide early drug design — shifting drug discovery from trial-and-error toward probability-driven development.

We are applying this approach across a pipeline of CNS and aging-related programs, including our lead program targeting mechanisms of brain repair and resilience.

Backed by top-tier research (Nature, Science) and strategic partners, ReneuBio is building a new paradigm for drug discovery — where molecules are designed not just for potency, but for clinical success.

ReneuBio Inc

Org chart

Teams

Offices